Lineage Cell Therapeutics
LCTX· Manufacturing· Fiscal year ends in December
Brian M. Culley is the CEO of Lineage Cell Therapeutics and was paid $2.1M in FY2025 (Dec), down 17%.
Executives3
See all- 1Brian M. CulleyChief Executive OfficerFY2025
- 2Jill A. HoweChief Financial OfficerFY2025
- 3George A. Samuel IIIGeneral Counsel and Corporate SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allLineage Cell Therapeutics paid its 3 named executives $4.1M in total in FY2025 (Dec). CEO Brian M. Culley was paid $2.1M of that.
| Name | |||
|---|---|---|---|
| Brian M. CulleyChief Executive Officer | |||
| Jill A. HoweChief Financial Officer | |||
| George A. Samuel IIIGeneral Counsel and Corporate Secretary |
of each named executive, from the Summary Compensation Table of each proxy.
Peers21
See allThe FY2025 (Dec) proxy of Lineage Cell Therapeutics names 21 peer companies for pay. Among Lineage Cell Therapeutics and these peers, CEO pay was 9th highest of 11 and total shareholder return was 5th highest of 11.
9th highest of 11in Lineage Cell Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
5th highest of 11in Lineage Cell Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
'%20fill='%23fff'/%3e%3cpath%20id='fullLogo-2'%20d='M18.156,40.577.011,29.356l0-18.125L18.147,0'%20transform='translate(-0.004%20-0.001)'%20fill='%23fff'/%3e%3cpath%20id='fullLogo-3'%20d='M35.133,14.327H26.354l4.389-7.163L35.127,0l4.395,7.164,4.389,7.163Z'%20transform='translate(-16.985)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-4'%20d='M51.052,93.782l0-8.211,18.178-3.019Z'%20transform='translate(-32.9%20-53.206)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-5'%20d='M69.213,11.223l-9.4,3.1L51.035,0Z'%20transform='translate(-32.892%20-0.001)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-6'%20d='M.01,11.23l9.387,3.1L18.148,0Z'%20transform='translate(-0.006%20-0.001)'%20fill='%2300b3cd'/%3e%3cpath%20id='fullLogo-7'%20d='M75.741,34.672l9.4-3.1,0,18.125Z'%20transform='translate(-48.815%20-20.345)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-8'%20d='M9.406,34.672l-9.4-3.1,0,18.125Z'%20transform='translate(-0.004%20-20.345)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-9'%20d='M18.15,93.786l.016-8.209L0,82.56Z'%20transform='translate(0%20-53.21)'%20fill='%233fbcd2'/%3e%3cpath%20id='fullLogo-10'%20d='M59.826,40.3,51.047,58.34l18.178-3.019Z'%20transform='translate(-32.9%20-25.974)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-11'%20d='M9.393,40.3l8.773,18.041L0,55.321Z'%20transform='translate(0%20-25.971)'%20fill='%2351c0d4'/%3e%3cpath%20id='fullLogo-12'%20d='M35.174,40.3H26.418l4.367,9.019,4.4,9.027,4.373-9.027,4.389-9.02Z'%20transform='translate(-17.026%20-25.974)'%20fill='%238fd4e2'/%3e%3c/svg%3e)
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Neal C. Bradsher, CFADirector · 16 yr on the boardIndependentFinancial Strategy, Nominating and Corporate Governance (Chair)—Paid as an executive
- Anula JayasuriyaDirector · 4 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 10, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 7, 2024 | FY2023 |
